|1.||Steiner, Alexandre A: 2 articles (12/2002 - 07/2002)|
|2.||Branco, Luiz G S: 2 articles (12/2002 - 07/2002)|
|3.||Izquierdo, I: 2 articles (03/2002 - 02/2001)|
|4.||Rodrigues, C: 2 articles (03/2002 - 02/2001)|
|5.||Medina, J H: 2 articles (03/2002 - 02/2001)|
|6.||He, Duan-Duan: 1 article (08/2014)|
|7.||Zhu, Gui-Qin: 1 article (08/2014)|
|8.||Liu, Su: 1 article (08/2014)|
|9.||Liu, Yue-Peng: 1 article (08/2014)|
|10.||Song, Xue-Jun: 1 article (08/2014)|
06/30/1993 - "Addition of Rp-cAMPS to the incubation media dose-dependently inhibited bone resorption induced by FSK (0.5 microM), with total inhibition obtained at 30 microM Rp-cAMPS. "
02/14/1992 - "Moreover, Rp-cAMPS (10(-4)M) antagonized 10(-7)M human PTH-(1-34)-induced stimulation of bone resorption, although it did not affect 10(-8)M 1,25(OH)2D3-induced stimulation of bone resorption. "
02/14/1992 - "Dibutyryl cAMP (dbcAMP)(10(-4)M) and Sp-cAMPS (10(-4)M) caused the remarkable stimulation of bone resorption. "
08/01/1993 - "Rp-cAMPs, an antagonist in the activation of PKA, equally attenuated bone resorption stimulated by PTHrP as well as by PTH. "
06/30/1993 - "In order to investigate the second messenger events that cause the osteoblasts to initiate bone resorption we have evaluated the effect of the cyclic AMP antagonist adenosine-3'5'-cyclic monophosphosphorothioate, Rp-isomer (Rp-cAMPS) on bone resorption in vitro, by measuring the release of prelabelled 45Ca from cultured neonatal mouse calvarial bones. "
06/01/2011 - "No non-specific adverse effect of Rp-cAMPS on myocytes was identified in a purified myocyte preparation during hypoxia/re-oxygenation. "
12/01/2002 - "Intra-PO microinjection of Rp-cAMPS, an inhibitor of cAMP-dependent protein kinase, attenuated hypoxia-induced anapyrexia. "
11/01/1999 - "(3) Hypoxia-induced catecholamine release from type I cells is inhibited by the protein kinase A antagonist, Rp-cAMPs. "
05/01/2002 - "Finally, inhibition of the cAMP/protein kinase A second-messenger system reduced the magnitude of the rise in pH(i) after anoxia in a manner that was dependent on external Na(+); conversely, activation of the system with isoproterenol increased the postanoxic alkalinization, an effect that was attenuated by pretreatment with propranolol, Rp-cAMPS, or when NMDG(+) (but not Li(+)) was employed as an external Na(+) substitute. "
08/01/2014 - "Spinal administration of the PKA inhibitor Rp-cAMPS during the early phase and late phase significantly delayed or reversed, respectively, TCI-induced thermal hyperalgesia and mechanical allodynia. "
02/01/1996 - "6. Rp-adenosine 3':5'-cyclic monophosphothioate (Rp-cAMPS; 1 nmol), an inhibitor of cyclic AMP-dependent protein kinase, significantly suppressed BK-induced mechanical hyperalgesia. "
11/01/2007 - "The positive inotropic effect was entirely blocked by prazosin, pertussis toxin, R(p)-adenosine 3',5'-cyclic monophosphorothioate, autosauvagine 30 or metyrapone, as well as by extirpation of the pituitary gland, functional elimination of the inter-renal glands and long-lasting starvation, and was not observed on isolated heart preparations. "
|2.||Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)
|3.||Parathyroid Hormone (Parathormone)
|4.||protein kinase modulator
|7.||Cyclic AMP (AMP, Cyclic)
|8.||GABA-A Receptor Agonists
|9.||Parathyroid Hormone-Related Protein